Characterization of Gut Microbiota Associated with Clinical Parameters in Intrahepatic Cholestasis of Pregnancy

Rong Li  
Chongqing Medical University First Affiliated Hospital

xuehai chen  
Chongqing Medical University First Affiliated Hospital  https://orcid.org/0000-0001-6319-1930

Zhongzhen Liu  
BGI-Shenzhen: BGI Group

Yan Chen  
BGI-Shenzhen: BGI Group

Chuan Liu  
BGI-Shenzhen: BGI Group

Lingfei Ye  
BGI-Shenzhen: BGI Group

Liang Xiao  
BGI-Shenzhen: BGI Group

Zhenjun Yang  
BGI-Shenzhen: BGI Group

Jian He  
BGI

Wen-Jing Wang  
BGI-Shenzhen: BGI Group

Hongbo Qi (✉ qihongbocy@gmail.com)

Research article

Keywords: Intrahepatic cholestasis, gut microbiota, 16S rRNA, preterm delivery, pregnancy

DOI: https://doi.org/10.21203/rs.2.18873/v4

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder that specifically occurs in pregnancy. Elevated levels of liver transaminases aspartate aminotransferase, alanine aminotransferase and serum bilirubin levels are common biochemical characteristics in ICP. The disorder is associated with an increased risk of premature delivery and stillbirth. The characterization of the potential microbiota in ICP could go a long way in the prevention and treatment of this pregnancy disease.

Methods

A total of 58 patients were recruited for our study: 27 ICP patients and 31 healthy pregnant subjects with no ICP. The V3 and V4 regions of the 16S rDNA collected from fecal samples of both diseased and control groups were amplified. 16S rRNA gene amplicon sequencing was then performed on gut microbiota. Sequencing data were analyzed and the correlation between components of microbiota and patient ICP status was found. Related metabolic pathways, relative abundance and significantly different OTUs (Operational Taxonomic Units) between ICP and controls were also identified.

Results

Elevated levels of total bile acid, ALT, AST, Dbil and Tbil were recorded or observed in ICP subjects as compared to the control. Gut microbiota in pregnant women was dominated by four major phyla and 27 core genera. PCoA analysis results indicated that there was no significant clustering in Bray-Curtis distance matrices. Our results showed that there was a correlation between specific OTUs and measured clinical parameters of pregnant women. Comparison at the different taxonomy levels revealed high levels of abundance of Blautia and Citrobacter in ICP patients. At the family level, Enterobacteriaceae and Leuconostocaceae were higher in ICP patients. 638 KEGG Orthologs and 138 pathways significantly differed in the two groups. PLS-DA model with VIP plots indicated a total of eight genera and seven species were key taxa in ICP and control groups.

Conclusions

Our research indicated that although there was no significant clustering by PCoA analysis, patients with ICP have increased rare bacteria at different phylogenetic levels. Our results also illustrated that all 638 KEGG Orthologs and 136 in 138 KEGG pathways were less abundant in ICP patients compared to the controls.

Background

Intrahepatic cholestasis of pregnancy (ICP) is a common liver disease that occurs during pregnancy. Globally, ICP incidence is reported to occur between 0.2% to 2% depending upon the sample region and ethnicity (1). Typical symptoms of ICP include itching without a rash that is typically localized to the soles of the feet and palms of the hands. Symptoms also include elevated levels of both liver enzymes and serum bilirubin. Fetal complications are more significant compared to maternally associated complications. In a large prospective national cohort study in the United Kingdom in 2014, women with severe ICP had significantly elevated risks of preterm delivery, stillbirth, and admissions for treatment into neonatal units as compared to control pregnant
subjects (2). Other symptoms that can affect the fetus include meconium-stained amniotic fluids, neonatal depression, and respiratory distress syndrome (3-5).

Although underlying mechanisms of ICP are not fully understood, several factors have been identified as being important. Reproductive hormones that encompass estrogens and progesterones have been implicated in the dynamics of the pathogenesis of ICP. Several studies that have examined data for animal-based models have unveiled the dynamics behind cholestatic effects of estrogen and its impact on hepatotoxicity (6-8). Researchers also found that the levels of progesterone metabolites were higher in ICP afflicted patients as compared to unafflicted patients, implying an adverse association (9). Ding et al., reported a higher risk of recurrence of ICP in patients with a family history (92%) as compared to their counterpart sporadic patients (40%) (10). Furthermore, genetic variants involved in the dynamics of bile acid synthesis and in transport pathways have been implicated in ICP progression. Mutations in the hepatocellular transport protein ABCB4 (MDR3), have been reported in more than 15% of ICP cases (11). There is also evidence that environmental factors also play important roles in the dynamics of ICP. A cross-sectional cohort study that recruited patients in Chile indicated that the prevalence of ICP was associated with seasonal variation, with the lowest recorded cases in summer months. This seasonal variation was found to coincide with higher levels of plasma Selenium concentrations in summer compared to other months, supporting the implication that nutrition is an important factor in the pathogenesis of ICP (12).

The relationship between gut microbiota and health has been increasingly extensively studied in recent years. As one of the most important factors related to individual health, gut microbiota has been implicated to play important roles in the dynamics of metabolism and immunity of hosts (13, 14). Some species of gut microbiota have been reported to synthesize vitamins as well as metabolize bile acids and sterols to benefit the hosts (15-18). Dysbiosis is related to various diseases related to cholestasis, including cirrhosis, cholangitis and etc. (19-21).

Crosstalk between gut microbiota and metabolism of bile acids has been extensively studied in recent times. Gut microbiota are involved in several processes that contribute to the metabolism of bile acids. Ridlon et al. reported that some bacteria mainly from the Clostridium and Eubacterium genera belonging to the Firmicutes phylum regulate CYP7A1, CYP7B1, and CYP27A1 (22), which play major roles in the metabolism of deconjugated primary bile acids into secondary bile acids through a series of enzymatic reactions. This occurs when there is deconjugation of glycine or taurine from bile acid which subsequently prevents its re-uptake by the small intestines resulting in entry of the aforementioned into the large intestines (23). Gut microbiota can also regulate bile acid synthesis indirectly via their influences upon receptors, such as FXR and FGF19 (22). Bile acids in their emulsifying nature are reported to most likely possess the ability to destroy bacterial membranes, thus increasing the transcription of anti-microbial factors through FXR, iNOS and IL-18 to induce an immune response (24). The dysregulation of microbiota-bile acid interactions also occurs in pathological states, including diet-induced obesity (25), cholestatic liver disease (26), gastrointestinal inflammation, and carcinogenesis (27).

Cirrhosis of the liver which is characterized by severe scarring of the liver and poor liver function is a typical model to illustrate the interrelation of biliary acids - portal blood - gut microbiota axis. In liver cirrhosis, increases in primary bile acid and cholic acid levels cause a dramatic shift toward the Firmicutes and lead to increased production of harmful secondary bile acid deoxycholic acid. The Firmicute microbiome are reported to cause inflammation, further suppressing the synthesis of bile acids in the liver, leading to a positive-feedback mechanism and progression of the pathology (20, 28).
Fecal samples from 27 pregnant women diagnosed with ICP and 31 healthy women as the control samples were collected in our study. DNA samples from the stool samples of the subjects were extracted which was followed by 16S rRNA sequencing using the amplicons from V3 and V4 region for all qualified DNA samples. Study and examination of potential changes in microbial diversity may provide a better understanding of the progression of ICP and thus lead to better preventive measures and treatment options for patients diagnosed with ICP.

Methods

Study Participants

This study was performed at the First Affiliated Hospital of Chongqing Medical University, China, between May 2015 and February 2016 with approval of all study aspects and granted from the Ethics Committee of The First Affiliated Hospital of Chongqing Medical University (No. 201530) and all study subjects involved the study. Written informed consent was also obtained from all participating patients.

Samples were collected from 27 patients that had been diagnosed with ICP. ICP diagnosis was done according to the following criteria: severe pruritus without rash; notably elevated concentrations of maternal serum bile acids (> 10 μM); absence of definitive itching-causing diseases; absence of other liver-damaging diseases, such as gallstones, hepatotoxic drug consumption, hepatitis, and inflammatory bowel diseases among others; no smoking or drinking histories and no antibiotics treatment from the onset of pregnancy till the fecal sample collection. Thirty-one age and BMI matched pregnant women unaFFECTed by ICP were recruited as controls for the study. All women included were Han nationality, without hepatitis B or pregnancy-induced hypertension (PIH), gestational diabetes mellitus (GDM), pre-eclampsia (PE) or other pregnancy-related syndromes.

Sampling

Stool samples from each of the subjects were collected after ICP diagnoses were confirmed during pregnancy, at consultations and before delivery (for the control samples). Stool samples collected had a normal appearance. After collection, samples were stored at -80 °C until further processed. Blood samples were also collected after patients had fasted to allow comparative examinations of biochemical parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total serum bilirubin (Tbil), direct bilirubin (Dbil), indirect bilirubin (Ibil) and total bile acid.

Stool DNA Extraction and Sequencing

DNA was extracted from stool samples following standard protocols and procedures (29). We targeted and quantified the expression level of amplicons amplified from the V3 and V4 regions of 16S rDNA for all qualified DNA samples. The primers used to amplify the region are: 341F: ACTCCTACGGGAGGCAGCAG and 806R: GGACTAC(A/T/C)(A/C/G)GGGT(A/T)TCTAAT. The amplicons were sequenced using the Miseq platform and 300-PE-cycles based upon standard protocols described in the literature (29).

Bioinformatics and Statistical Analysis

The quality of sequenced reads was assessed with the use of an in-house developed pipeline, which filtered the low-quality data, ambiguous bases, low complexity of reads, and adapter reads as previously described (29). PE-reads with acceptable levels of quality were then assembled into tags. Operational taxonomic units (OTUs) were
clustered using a $\geq 97\%$ similarity threshold for tags with Uparse (version 7.0.1090) using all default settings in the Uparse OTU analysis pipeline program (30). OTUs were taxonomically annotated using Ribosomal Database Project (RDP, release 11) with a bootstrap cutoff of 80% similar to previous similar studies (31, 32). Alpha diversity was calculated using Mothur (version 1.31.2) (33). Corresponding rarefaction curves and box graphs or histograms were plotted by using R statistics software (34). A particular number of reads were drawn at a time. The initial amount was 1,000, followed subsequently by addition of 8,000 reads for each cycle with the highest number of reads at 81,000. The number of iterations per round was 10. The number of OTUs obtained each time was recorded and the corresponding rarefaction curves were plotted.

Beta diversity was measured by Bray-Curtis with the function “beta_diversity.py” in the QIIME pipeline (35). Principal coordinate analysis (PCoA) analysis was performed using QIIME based on the Bray-Curtis distance. The results from PCoA were plotted using GraphPad Prism 5 software, and the 95% confidence interval ellipse was drawn by ggplot2 (36). A partial least squares discriminant analysis (PLS-DA) with a variable importance in projection (VIP) plot (37) was performed to determine possible differences in OTUs between ICP patients. This would help in predicting the functional contents of the metagenome. The key genera with VIP > 1.6 were considered important contributors to the model. The KEGG Orthologs and pathway analysis were done by Picrust2.

All biochemical parameters were expressed as the boxplots. Non-parametric Mann-Whitney tests with resultant $p$-values $\leq 0.05$ were considered as statistically significant between comparisons of ICP patients and controls. The relative abundance at 95% confidence intervals for differences between ICP patients and controls at a series of taxonomic levels was calculated by using a non-parametric Mann-Whitney test for determination of the false discovery rate (FDR, n=6). Pearson's correlation coefficients between OTUs and six biochemical parameters (ALT, AST, total bile acid, Tbil, Ibil, and Dbil) were quantified and compared using the cor.test function in the R Statistics suite with all default parameters. The Geom boxplot and geom jitter functions in the ggplot2 package in R statistics were utilized in drawing results for the six biochemical parameters.

**Results**

In total, 27 ICP patients and 31 controls were enrolled in our study. Basic clinical information for subjects is summarized in Table 1 and Figure 1. Age brackets were similar and in very close range for both ICP and control groups. ICP patients and control subjects were sampled at ~ 35.0 and ~39.4 weeks respectively. Mean values of total bile acid, ALT, AST, Dbil, and Tbil were all significantly higher in ICP patients than in the control group (Figure 1, Table 1). Ibil mean values for ICP patients were relatively higher than the value in controls (4.7 ± 0.8 versus 3.2 ± 0.6).

**Table 1. Study subjects characteristics.**
|                                | ICP (n=27) | Control (n=31) |     | IQR |     | p-value(adj.) |
|--------------------------------|------------|----------------|-----|-----|-----|---------------|
|                                | Mean ± SE  | IQR            | Mean ± SE | IQR |      |               |
| Age (year)                     | 29.0 ± 1.0 | 7              | 29.0 ± 0.79 | 6   | 0.5573 |               |
| Sampling pregnancy weeks (week)| 35.0 ± 0.38 | 3.5            | 39.4 ± 0.26 | 2   | 1.97E-09 |               |
| Total bile acid (μmol/L)       | 41.6 ± 6.9 | 57.1           | 8.8 ± 0.5 | 3.3 | 8.51E-06 |               |
| Tbil (μmol/L)                  | 18.5 ± 2.3 | 12             | 7.0 ± 0.4 | 2.9 | 2.56E-05 |               |
| Ibil (μmol/L)                  | 4.7 ± 0.8  | 4.3            | 3.2 ± 0.6 | 5.2 | 0.8637796 |               |
| Dbil (μmol/L)                  | 13.4 ± 1.9 | 11             | 3.9 ± 0.4 | 3.8 | 3.16E-07 |               |
| AST (U/L)                      | 140 ± 24.6 | 164            | 20.7 ± 1.0 | 3   | 2.90E-06 |               |
| ALT(U/L)                       | 193.3 ± 34.4 | 285          | 18.6 ± 1.2 | 9   | 3.22E-05 |               |

Tbil: Total serum bilirubin; Ibil: Indirect bilirubin; Dbil: Direct bilirubin; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; SE: Standard Error. The p-values were calculated using Mann-Whitney U test with a Bonferroni correction.

**Characterizing Gut Microbiota in Women with ICP and controls**

16S rRNA amplicon-based microbiome analysis was performed on stool samples from 27 ICP patients and 31 healthy controls. After sequencing using the Miseq platform and preliminary data processing, clean reads were assembled into tags. Similar numbers of tags (on average 89265 ± 17127 tags for each ICP patient and 90964 ± 13947 tags for each control) were clustered into OTUs. A total of 875 OTUs were found from all samples. There was no significant difference in the identified OTUs between the two groups (median = 234 for ICP patients and 238 for controls, p = 0.3944, Figure S1 A, Additional File 1). Alpha diversity analyses revealed that the number of OTUs in ICP patients was 9.8 % lower than controls (p = 0.0165). Alpha rarefaction curves of numbers of observed OTUs for both patient groups showed a gradual leveling off by 60,000 sequences. The average number of reads for each sample was 287,000, which was much more than 60,000. (Figure S1 B, Additional File 1).

Collectively, the composition of gut microbiota of pregnant women was dominated by four major phyla: *Firmicutes*, *Bacteroidetes*, *Actinobacteria*, and *Proteobacteria*, all of which existed in more than 95 % of these samples. At the genus level, 27 core genera that included *Faecalibacterium*, *Streptococcus* and *Escherichia* existed in more than 95 % of the samples from pregnant women (Table S1, Additional File 1).

To assess the structural similarities in the gut microbiota communities between the ICP patients and controls, a principle coordinates analysis (PCoA) was generated based on Bray-Curtis distance. The analysis is primarily based on the number of OTUs and not the specific taxonomic annotation. The PCoA results showed no separation of the ICP patients from the control group, indicating that the main composition of the gut microbiome of the ICP group was not significantly different from the control group (Figure 2, ANOSIM, p = 0.26).
The alpha-diversity between ICP patients and controls was also assessed. The five measures (Chao, ace, sobs, Shannon, simpson) were used to analyze the abundance and diversity of microbiota within samples. None of the five measures showed any significant differences between the two groups (Figure S2 & Table S2, Additional File 1).

The correlation coefficient between OTUs and clinical parameters was examined. The correlation between bacterial species (with prevalence ≥ 20%) and clinical parameters in ICP group was also assessed and no bacteria was identified or found. A subsequent slight change in conditions was made to aid observation of the correlated OTUs for clinical parameters in both ICP patients and controls. We observed the associations between specific microbiota and some liver parameters. Results showed that:

1. *Roseburia* and *Dorea* were positively associated with ALT.
2. *SMB53, Roseburia, H. parainfluenzae, S. anginosus, L. rogosae* and *R. hominis* showed some encouraging association with total bile acid.
3. *O. coprococcus, H. parainfluenzae, B. pullicaecorum, R. mucilaginosa, R. lactaris, R. champanellensis* were associated with Dbil.
4. Associations between *Paraprevotella, Dorea, Roseburia* and *B. product* with AST, *R. champanellensis* and *L. pacaense* with Tbil and *B. plebeius* and *L. pacaense* with Ibil were observed as shown in Figure 3.

The Mann-Whitney U test (with an FDR correction) was then utilized in finding the differential relative abundances of bacteria at different taxonomy levels. As shown in Table 2, the abundance of *Blautia, Citrobacter* and *Streptococcus* at the genus level, was significantly higher in ICP patients than in controls. Similarly at the family level, *Enterobacteriaceae, Leuconostocaceae* and *Streptococcaceae* were higher in ICP patients. *Bacilli* and *Gammaproteobacteria* and *Enterobacteria* and *Lactobacillales* levels were higher at the class and order levels respectively. *Streptococcus luteciae*, at the species level was higher in ICP patients (Figure 4, Table 2). All these bacteria were considered to be rare (mean relative abundance < 5 %) in both the ICP patients and controls.

**Table 2. Differential relative abundances of bacteria in six levels**

---

[The rest of the document continues with more detailed analysis and results.]
| Items               | Mean(ICP) | SD(ICP) | Mean(Nor) | SD(Nor) | p-value  | FDR       |
|--------------------|-----------|---------|-----------|---------|----------|-----------|
| **Bacilli**        | 0.0038    | 0.0058  | 0.0014    | 0.0018  | 0.0055   | 0.015548  |
| **Gammaproteobacteria** | 0.0311    | 0.0636  | 0.0052    | 0.0085  | 0.0070   | 0.022667  |
| **Enterobacteriales** | 0.0282    | 0.0633  | 0.0033    | 0.0063  | 0.0021   | 0.032923  |
| **Lactobacillales** | 0.0033    | 0.0057  | 0.0011    | 0.0017  | 0.0007   | 0.008636  |
| **Enterobacteriaceae** | 0.0282    | 0.0633  | 0.0033    | 0.0063  | 0.0021   | 0.0282    |
| **Leuconostocaceae** | 8.013E-05 | 2.095E-04 | 3.314E-06 | 1.402E-05 | 9.065E-04 | 0.006011  |
| **Streptococcaceae** | 0.0029    | 0.0055  | 0.0008    | 0.0009  | 0.0041   | 0.006011  |
| **Blautia**        | 0.0168    | 0.0121  | 0.0084    | 0.0062  | 0.0009   | 0.026867  |
| **Citrobacter**    | 3.087E-04 | 5.472E-04 | 8.751E-06 | 1.978E-05 | 2.218E-05 | 0.007293  |
| **Streptococcus**  | 2.826E-03 | 5.532E-03 | 7.179E-04 | 8.808E-04 | 1.782E-02 | 0.026867  |
| **Streptococcus luteciae** | 2.148E-04 | 3.561E-04 | 7.496E-05 | 1.036E-04 | 1.057E-02 | 2.148E-04 |

SD: Standard Deviation. The p-value is calculated by using Mann-Whitney U test with an FDR (n=6).

The functional profile of the gut microbiota from ICP patients and controls was also explored. The total OTUs were normalized by 16S rDNA copy number. The KEGG orthologs, Enzyme Classification and metagenomic functions were predicted from the KEGG pathways. A total of 638 KEGG Orthologs were identified significantly different between ICP patients and controls, all of which were less abundant in ICP patients (P < 0.05; Additional File 2). A total of 138 pathways were identified significantly different between the two groups, whereas 136 pathways were significantly more abundant in controls (P < 0.05; Additional File 3). Of these KEGG Orthologs, the greatest difference was observed among RNA polymerase primary sigma factor between the two groups (Figure 5 A). To the KEGG pathways, the greatest difference was observed among ketogluconate metabolism which was more represented in ICP patients than in controls (Figure 5 B).

The contribution of the taxa to the discrimination between ICP patients and controls was assessed by PLS-DA model and VIP score. PLS-DA score plot showed model discrimination between ICP patients and controls. A total of eight genera and seven species were recorded with VIP > 1.6. These were identified as key genera/species in ICP and control group. Of these, five were more abundant in ICP patients whereas the remaining 10 were more abundant in controls. Blautia genus (~2.6) and [C.] methylpentosum species (~2.3) recorded the highest VIP scores (Figure 6).

**Discussion**

In this study, we analyzed gut microbiota in the third-trimester of sections of ICP pregnant women and healthy control pregnant women. As at the time of our study, the relationship between gut microbiota and ICP was studied for the first time and no previous reports had been made to our knowledge. Correlation coefficients
between OTUs and clinical parameters (liver) of ICP patients and controls at different taxonomic levels were determined. In addition, we assessed the contribution of the genera or species to the discrimination between ICP patients and controls. It was observed when a collective study of bacteria from both study groups done that, Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria were the dominant phyla, whereas 27 core genera including Faecalibacterium, Streptococcus, Escherichia were the dominant genera in both groups. The compositions of these taxa were found to be in accordance with a previous study by Koren et al., which focused on changes of microbiota during pregnancy. In their study, the relative abundances of Proteobacteria and Actinobacteria increased as the pregnancy progressed. In our study, OTUs including members of the Enterobacteriaceae family and Streptococcus genus were dominant in the third trimester which was similar to previous reports by Koren et al. (38). In a cohort study of 314 young Chinese individuals conducted by Zhang et al., a list of 16 abundant genera were reported in their fecal samples. Eleven of these were included in our core genera list, further validating our data (39).

While few studies focused upon the flora making up the gut microbiota in patients with ICP, some teams have studied the metagenomes in bile acid-related abnormality or liver diseases. A series of studies examined gut microbiota for patients with cirrhosis (17, 20, 28, 40). It was reported that when levels of observed bile acid entering the intestine that were low, levels of Enterobacteriaceae (the only one family belonging to Enterobacteriales) was found to have increased. In a study that examined primary sclerosing cholangitis (PSC), it was observed that there were high levels Blautia when there was inhibition of bile released in the small intestines (41). We obtained similar results in our experiments. Intestinal bile acid is one of the major regulators of gut microbiota and inhibition of the entrance of bile acid to intestines causes bacterial dysbiosis, as gram-positive members such as Ruminococcaceae and members of Clostridium cluster XIVa, which are involved in secondary fecal bile acid production and anti-inflammatory response, were inhibited (23). Contrastingly, pro-inflammatory and potentially pathogenic taxa, including Enterobacteriaceae, increased (40).

Bile acids affect gut microbiota composition directly through antimicrobial effects or indirectly through impacts upon FXR-dependent antimicrobial peptides. As one of the components of the pool of bile acids, deoxycholic acid (DCA), has a strong effect upon inhibiting the growth of the microbiome and acts as a detergent upon bacterial membranes (42).

In our study, women with ICP were sampled at a median time of pregnancy of 35.0 weeks (i.e. before full-term) and control women were sampled at a median of 39.4 weeks (i.e. at term). A previous study that examined temporal variation in the composition of human microbiota during pregnancy evaluated the communities sampled in consecutive weeks through delivery and found that there were no significant trends over gestational time (P > 0.05, t-test) (43). Thus, in our study, we felt it was appropriate and reasonable to have collected samples at different time points in the third trimester.

In conclusion, our study presented the first view of research which examined the gut microbiota of ICP afflicted patients. Although the mechanisms and dynamics with regards to how phylogenetic diversity changes gut microbiota in patients afflicted with ICP remain obscure, our findings might provide new diagnostic and treatment strategies during pregnancy for this disease and the associated symptoms. Further studies are needed to identify factors impacting gut bacterial composition in ICP patients to prevent the occurrence and progression of these complications in the third trimester of pregnancy.
Conclusions

In this study, the fecal microbiota from 27 ICP patients and 31 comparable controls were analyzed by 16S rRNA gene amplicon sequencing. The differential relative abundances of bacteria at different taxonomy levels between ICP patients and controls were compared and the correlation between OTUs and clinical liver characters was explored. The functional profile of the gut microbiota from ICP patients and controls were compared. The contribution of the genera or species to the discrimination between ICP patients and controls was assessed. Our results indicated for the first time that patients with ICP have an altered phylogenetic gut microbiota profile compared with the control group.

Declarations

Ethics approval and consent to participate

This study was performed with the approval of all study subjects granted from the Ethics Committee of The First Affiliated Hospital of Chongqing Medical University, P.R. China (No. 201530). Written informed consent was obtained from all participating subjects.

Consent for publication

Not applicable.

Availability of data and materials

The datasets generated and analysed during the current study are available in the CNSA (https://db.cngb.org/cnsa/) of CNGBdb repository, with the accession code CNP0000403.

Competing interests

The authors declare that they have no competing interests.

Funding

This project is supported by National Key Research and Development Program of Reproductive Health & Major Birth Defects Control and Prevention (No. 2016YFC1000407), Key Program of International Cooperation of NSFC (No. 81520108013) and National Natural Science Foundation of China for Youth (No. 31501207, No. 81300075), the Natural Science Foundation of Guangdong Province (No. 2014A030313795), the Shenzhen Municipal Government of China (No. JCYJ20170412152854656, JCYJ20180703093402288). We also would like to appreciate the support from “111 program” of Ministry of Education P. R. C and State Administration of Foreign Experts Affairs P. R. C. and Guangdong Enterprise Key Laboratory of Human Disease Genomics (2011A060906007), Shenzhen Engineering Laboratory for Birth Defects Screening (DRC-SZ[2011]861). The funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Authors’ contributions
Concept and design: W-J W, HB Q; Samples and clinical data collection: R L, XH C; Data analysis and interpretation: ZZ L, R L, XH C, Y C, C L, LF Y, L X, ZJ Y, J H; Drafting of the manuscript: W-J W, HB Q; Critical revision of the manuscript: R L, XH C, ZZ L, W-J W, HB Q. All authors have read and approved the final manuscript.

Acknowledgements

The authors would like to thank Taifu Wang for helpful discussions, and all study participants for generously providing their time, data, and samples.

Abbreviations

ICP: Intrahepatic Cholestasis of Pregnancy;
ALT: Alanine Aminotransferase;
AST: Aspartate Aminotransferase;
Tbil: Total Serum Bilirubin;
Dbil: Direct Bilirubin;
Ibil: Indirect Bilirubin;
OTUs: Operational Taxonomic Units;
RDP: Ribosomal Database Project;
PCoA: Principal Coordinate Analysis;
FDR: False Discovery Rate;
IQR: Interquartile Range;
PLS-DA: partial least squares discriminant analysis;
VIP: variable importance in projection;
SCFA: Short-Chain Fatty Acids;
DCA: Deoxycholic Acid.

References

1. Wood AM, Livingston EG, Hughes BL, Kuller JA. Intrahepatic Cholestasis of Pregnancy: A Review of Diagnosis and Management. Obstet Gynecol Surv. 2018;73(2):103-9.

2. Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control
study. Hepatology. 2014;59(4):1482-91.

3. Kenyon AP, Piercy CN, Girling J, Williamson C, Tribe RM, Shennan AH. Obstetric cholestasis, outcome with active management: a series of 70 cases. BJOG. 2002;109(3):282-8.

4. Zecca E, De Luca D, Marras M, Caruso A, Bernardini T, Romagnoli C. Intrahepatic cholestasis of pregnancy and neonatal respiratory distress syndrome. Pediatrics. 2006;117(5):1669-72.

5. Brouwers L, Koster MP, Page-Christiaens GC, Kemperman H, Boon J, Evers IM, et al. Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels. Am J Obstet Gynecol. 2015;212(1):100 e1-7.

6. Crocenzi FA, Mottino AD, Cao J, Veggi LM, Pozzi EJ, Vore M, et al. Estradiol-17beta-D-glucuronide induces endocytic internalization of Bsep in rats. Am J Physiol Gastrointest Liver Physiol. 2003;285(2):G449-59.

7. Simon FR, Fortune J, Iwahashi M, Qadri I, Sutherland E. Multihormonal regulation of hepatic sinusoidal Ntcp gene expression. Am J Physiol Gastrointest Liver Physiol. 2004;287(4):G782-94.

8. Yamamoto Y, Moore R, Hess HA, Guo GL, Gonzalez FJ, Korach KS, et al. Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. J Biol Chem. 2006;281(24):16625-31.

9. Lammert F, Marschall HU, Glantz A, Matern S. Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J Hepatol. 2000;33(6):1012-21.

10. Savander M, Ropponen A, Avela K, Weerasekera N, Cormand B, Hirvioja ML, et al. Genetic evidence of heterogeneity in intrahepatic cholestasis of pregnancy. Gut. 2003;52(7):1025-9.

11. Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet. 1999;353(9148):210-1.

12. Reyes H, Baez ME, Gonzalez MC, Hernandez I, Palma J, Ribalta J, et al. Selenium, zinc and copper plasma levels in intrahepatic cholestasis of pregnancy, in normal pregnancies and in healthy individuals, in Chile. J Hepatol. 2000;32(4):542-9.

13. Lebba V, Nicoletti M, Schippa S. Gut microbiota and the immune system: an intimate partnership in health and disease. Int J Immunopathol Pharmacol. 2012;25(4):823-33.

14. Chung H, Kasper DL. Microbiota-stimulated immune mechanisms to maintain gut homeostasis. Curr Opin Immunol. 2010;22(4):455-60.

15. Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, Dinan TG. MiniReview: Gut microbiota: the neglected endocrine organ. Mol Endocrinol. 2014;28(8):1221-38.

16. Lebba V, Totino V, Gagliardi A, Santangelo F, Cacciotti F, Trancassini M, et al. Eubiosis and dysbiosis: the two sides of the microbiota. New Microbiol. 2016;39(1):1-12.

17. Shin NR, Whon TW, Bae JW. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015;33(9):496-503.

18. Sommer F, Anderson JM, Bharti R, Raes J, Rosenstiel P. The resilience of the intestinal microbiota influences health and disease. Nat Rev Microbiol. 2017;15(10):630-8.

19. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003;361(9356):512-9.

20. Ridlon JM, Alves JM, Hylemon PB, Bajaj JS. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes. 2013;4(5):382-7.
21. Liao L, Schneider KM, Galvez EJC, Frissen M, Marschall HU, Su H, et al. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. Gut. 2019;68(8):1477-92.

22. Sayin SI, Wahlstrom A, Felin J, Jantti S, Marschall HU, Bamberg K, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17(2):225-35.

23. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol. 2014;30(3):332-8.

24. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006;103(10):3920-5.

25. Zheng X, Huang F, Zhao A, Lei S, Zhang Y, Xie G, et al. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice. BMC Biol. 2017;15(1):120.

26. Li Y, Tang R, Leung PSC, Gershwin ME, Ma X. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev. 2017;16(9):885-96.

27. Jia W, Xie G, Jia W. Bile-acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15(2):111-28.

28. Iebba V, Guerrieri F, Di Gregorio V, Levrero M, Gagliardi A, Santangelo F, et al. Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. Sci Rep. 2018;8(1):8210.

29. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55-60.

30. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 2013;10(10):996-8.

31. Cole JR, Wang Q, Fish JA, Chai B, McGarrell DM, Sun Y, et al. Ribosomal Database Project: data and tools for high throughput rRNA analysis. Nucleic Acids Res. 2014;42(Database issue):D633-42.

32. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol. 2006;72(7):5069-72.

33. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol. 2013;79(17):5112-20.

34. Orakov AN, Sakenova NK, Sorokin A, Goryanin, II. ASAR: visual analysis of metagenomes in R. Bioinformatics. 2018;34(8):1404-5.

35. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7(5):335-6.

36. Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005;71(12):8228-35.

37. Xu M, Jiang Z, Huang W, Yin J, Ou S, Jiang Y, et al. Altered Gut Microbiota Composition in Subjects Infected With Clonorchis sinensis. Front Microbiol. 2018;9:2292.

38. Koren O, Goodrich JK, Cullender TC, Spor A, Laitinen K, Backhed HK, et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell. 2012;150(3):470-80.
39. Zhang J, Guo Z, Xue Z, Sun Z, Zhang M, Wang L, et al. A phylo-functional core of gut microbiota in healthy young Chinese cohorts across lifestyles, geography and ethnicities. ISME J. 2015;9(9):1979-90.

40. Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013;58(5):949-55.

41. Torres J, Bao X, Goel A, Colombel JF, Pekow J, Jabri B, et al. The features of mucosa-associated microbiota in primary sclerosing cholangitis. Aliment Pharmacol Ther. 2016;43(7):790-801.

42. Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev. 2005;29(4):625-51.

43. DiGiulio DB, Callahan BJ, McMurdie PJ, Costello EK, Lyell DJ, Robaczewska A, et al. Temporal and spatial variation of the human microbiota during pregnancy. Proc Natl Acad Sci U S A. 2015;112(35):11060-5.